BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mills L, Lintzeris N, O'Malley M, Arnold JC, McGregor IS. Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug Alcohol Rev 2022. [PMID: 35172040 DOI: 10.1111/dar.13444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lewis N, Eliash-Fizik H, Har-Even A, Sznitman SR. Media Framing of Causes, Risks, and Policy Solutions for Cannabis-Impaired Driving: Does Medical vs. Non-Medical Cannabis Context Matter? Health Commun 2023;:1-10. [PMID: 36914573 DOI: 10.1080/10410236.2023.2187956] [Reference Citation Analysis]
2 Matson TE, Lapham GT, Bobb JF, Oliver M, Hallgren KA, Williams EC, Bradley KA. Validity of the Single-Item Screen-Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care. JAMA Netw Open 2022;5:e2239772. [PMID: 36318205 DOI: 10.1001/jamanetworkopen.2022.39772] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 English F, Greyson D. "You still have that fear": Policy constraints on informed decision making about legalized cannabis use during pregnancy and lactation. Int J Drug Policy 2022;106:103774. [PMID: 35772267 DOI: 10.1016/j.drugpo.2022.103774] [Reference Citation Analysis]